Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
4 - MANGOCEUTICALS, INC. (0001938046) (Issuer)
4 - MANGOCEUTICALS, INC. (0001938046) (Issuer)
4 - MANGOCEUTICALS, INC. (0001938046) (Issuer)
8-K - MANGOCEUTICALS, INC. (0001938046) (Filer)
144 - MANGOCEUTICALS, INC. (0001938046) (Subject)
10-Q - MANGOCEUTICALS, INC. (0001938046) (Filer)
Dallas, Texas, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) ("Mangoceuticals" or the "Company") is issuing the following clarification regarding its press release issued earlier this morning titled "Mangoceuticals Partners with Eli Lilly and Novo Nordisk…". The newly launched Mangoceuticals weight-management programs MangoRx Direct and PeachesRx Direct are licensed and approved to issue, through a third-party provider, valid prescriptions for FDA-approved branded GLP-1 medications, including, when medically appropriate, Zepbound® from Eli Lilly and Wegovy® from Novo Nordisk. These programs allow Mangoceuticals patients to access, for the first time, Eli Lilly and N
Dallas, Texas, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) ("Mangoceuticals" or the "Company"), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx, and a pioneer in innovative wellness solutions, is excited to announce that it has launched MangoRx Direct and PeachesRx Direct, two integrated programs that provide direct access to authentic Zepbound® (tirzepatide) from Eli Lilly and Wegovy® (semaglutide) from Novo Nordisk. These branded GLP-1 medications will be made available to both MangoRx and PeachesRx customers via Eli Lilly's LillyDirect® Se
Dallas, TX, May 27, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) ("Mangoceuticals" or the "Company"), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx, and a pioneer in innovative wellness solutions, is excited to share groundbreaking results from field studies based on its patented antiviral compound which it refers to as "MGX-0024". The field studies were conducted by Solice International at Duraiswamy Farm in Palladam, Tamil Nadu, India. These studies, targeting respiratory diseases in chickens, like Newcastle Disease and Chronic Respiratory Disease (
Dallas, TX, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling men's health and wellness products via a secure telemedicine platform, today announced the acquisition of patent number WO 2023/086647 PCT/US2022/049857, for mushroom-derived compositions and methods of treatment. This new addition to MangoRx's intellectual property portfolio highlights the Company's commitment to innovative solutions that support holistic health and wellness. The acquired patent encompasses nutraceutical compositions derived from functional mushrooms, including well-known varieties such as Cordyceps sinensi
Dallas, Texas, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling a variety of men's health and wellness products in the area of erectile dysfunction (ED), hair growth, weight loss, and hormone replacement therapies, today announced its financial results for the three and six months ending June 30, 2024, showing a significant growth in both shareholder's equity and gross revenues. During the six months ending June 30, 2024, MangoRx's shareholder equity increased to $13,829,445, compared to $774,754 as of December 31, 2023, reflecting an increase of 1,685%, or $13,054,691. A substantial
DALLAS, TX, April 25, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals Inc. (NASDAQ:MGRX) ("Mangoceuticals" or "MGRX"), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx, is pleased to announce that it has entered into an Intellectual Property Purchase Agreement to acquire all intellectual property, product formulations, know-how, distribution, supplier relationships and related assets of Smokeless Technology Corp. ("Smokeless Tech"), a Canadian-based pouch innovation company specializing in stimulant and functional pouches. This acquisition marks a strategic expansion into the
SC 13D/A - MANGOCEUTICALS, INC. (0001938046) (Subject)
SC 13D/A - MANGOCEUTICALS, INC. (0001938046) (Subject)